摘要
同种异体造血干细胞移植是对称为Fanconi贫血(FA)的非恶性骨髓衰竭综合征的患者的唯一治疗性治疗。 然而,与这种方法相关的早期和晚期并发症强调了对替代治疗的需要。 旨在纠正患者自身造血干细胞中的遗传缺陷的基因治疗方法仍然是克服FA相关的骨髓衰竭的最有希望的策略。 然而,尽管二十多年的临床研究,治疗“成功”还没有实现。 在这里我们审查迄今为止进行的临床试验,并突出显示这些研究揭示的FA的独特功能。 这些功能使FA成为造血干细胞基因治疗方法的“圣杯”,并确定在这种罕见疾病中实现临床成功所需的未来步骤。
关键词: Fanconi贫血,临床试验,基因治疗,骨髓衰竭,干细胞,病毒载体。
Current Gene Therapy
Title:Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia
Volume: 16 Issue: 5
关键词: Fanconi贫血,临床试验,基因治疗,骨髓衰竭,干细胞,病毒载体。
摘要: Allogeneic hematopoietic stem cell transplantation is the only curative treatment for patients with the non-malignant bone marrow failure syndrome called Fanconi anemia (FA). However, early and late complications associated with this approach underscore the need for alternative treatments. Gene therapy approaches aiming to correct the genetic defect in the patient’s own hematopoietic stem cells remain the most promising strategy to overcome FA-associated bone marrow failure. Yet, despite more than two decades of clinical research, a therapeutic “success” has not yet been achieved. Here we review the clinical trials conducted to date and highlight the unique features of FA revealed by these studies. These features render FA the “holy grail” of hematopoietic stem cell gene therapy approaches, and identify the future steps required to achieve clinical success in this rare disease.
Export Options
About this article
Cite this article as:
Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia, Current Gene Therapy 2016; 16 (5) . https://dx.doi.org/10.2174/1566523217666170119113029
DOI https://dx.doi.org/10.2174/1566523217666170119113029 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry Chalcones as Promising Lead Compounds on Cancer Therapy
Current Medicinal Chemistry Piperidin-4-one: The Potential Pharmacophore
Mini-Reviews in Medicinal Chemistry Evaluation of Vitamin C as a Personalized Adjuvant Medicine: Pharmacogenomic Studies
Current Pharmacogenomics and Personalized Medicine Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design Defining the Role of Integrin αvβ6 in Cancer
Current Drug Targets Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Current Pharmaceutical Biotechnology A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Current Gene Therapy PP2A in the Regulation of Cell Motility and Invasion
Current Protein & Peptide Science Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Role of Sequence Variations in <i>AhR</i> Gene Towards Modulating Smoking Induced Lung Cancer Susceptibility in North Indian Population: A Multiple Interaction Analysis
Current Genomics Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors
Recent Patents on Anti-Cancer Drug Discovery Role of Thymidine Phosphorylase in Biomodulation of Fluoropyrimidines
Current Pharmaceutical Biotechnology The Role of Chemotherapy and Radiation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Multidimensional Ophthalmic Nanosystems for Molecular Detection and Therapy of Eye Disorders
Current Pharmaceutical Design Micro-/Nano-Scale Biointerfaces, Mechanical Coupling and Cancer Therapy
Current Topics in Medicinal Chemistry Oncoproteomics of Neuroblastoma: A Blueprint for Future Progress
Current Proteomics Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Role of the Non-Neuronal Human Cholinergic System in Lung Cancer and Mesothelioma: Possibility of New Therapeutic Strategies
Current Medicinal Chemistry - Anti-Cancer Agents